Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), ...

The abrupt exit of the former CBER director, who quickly made his mark at the agency with several high-profile and ...

Prasad’s short FDA tenure brought stricter review standards for gene and COVID vaccines, sparking biotech concern and political backlash.

The SPDR® S&P Biotech ETF rebounded over 20% since lows in April, despite changes at the FDA that could have signaled a ...

US stock futures rise before Fed as Wall Street holds its breath for a pivotal decision on interest rates and key earnings reports from tech giants like Microsoft and Meta. Markets are slightly up on ...